August 2, 2024

Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast

Key Points

Key points are not available for this paper at this time.

Abstract

The objective of this investigation was to assess the impact of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive and HER2-negative metastatic breast cancer (mBC) who received palbociclib as first-line or successives therapy.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Criado et al. (Fri,) studied this question.

www.synapsesocial.com/papers/68e5d9f4b6db643587570168 — DOI: https://doi.org/10.1177/10781552241269677

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Authors

Javier Álvarez Criado

Pilar Auñón

Virginia Martínez Marín

Journals

Journal of Oncology Pharmacy Practice

Actions

Institutions

Universidad Complutense de Madrid

Hospital Universitario La Paz

Comunidad de Madrid

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion